melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-03. Numbers and descriptions here follow the published literature rather than marketing material.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Unless these long-term fiscal imbalances are addressed by reforms to these programs, raising taxes or drastic cuts in discretionary programs, the federal government will at some point be unable to pay its obligations without significant risk to the value of the dollar (inflation). By one estimate, 70% of the growth in these entitlement expenses over the 2016-2046 period is due to healthcare.
=== Advantages === Cannot revert to virulence meaning they cannot cause the disease they aim to protect against Safe for immunocompromised patients Can withstand changes in conditions (e.g. temperature, light exposure, humidity)
== Technology overview == In analytical chromatography, the goal is to separate and uniquely identify each of the compounds in a substance. Alternatively, preparative scale chromatography is a method of purification of large batches of material in a production environment. The basic methods of separation in HPLC rely on a mobile phase (water, organic solvents, etc.) being passed through a stationary phase (particulate silica packings, monoliths, etc.) in a closed environment (column); the differences in reactivity among the solvent of interest and the mobile and stationary phases distinguish compounds from one another in a series of adsorption and desorption phenomena. The results are then visually displayed in a resulting chromatogram. Stationary phases are available in many varieties of packing styles as well as chemical structures and can be functionalized for added specificity. Monolithic-style columns, or monoliths, are one of many types of stationary phase structure. Monoliths, in chromatographic terms, are porous rod structures characterized by mesopores and macropores. These pores provide monoliths with high permeability, a large number of channels, and a high surface area available for reactivity. The backbone of a monolithic column is composed of either an organic or inorganic substrate in, and can easily be chemically altered for specific applications. Their unique structure gives them several physico-mechanical properties that enable them to perform competitively against traditionally packed columns.
Narrated by John Hedges, produced by Brian Johnson, made by Uden Associates 23 September Trouble on the Line, with Richard Hope and Roger Ford rail journalists, Chris Green, the Head of Network SouthEast; mention of a possible Crossrail and the new Thameslink, which was a redeveloped former freight tunnel; Andrew Higton; Bob Walters the InterCity 225 project engineer; London had the biggest commuter system in world; Borough Market Junction is a bottleneck; Jim Vine head of the new Networker train project; BR carried 700 million people; 134,000 BR employees; at Department of Transport 2300 worked on the roads, and 135 on rail; Dornoch Firth Bridge (A9), shown being built, it saved twenty miles, and could have had a rail bridge too for the Far North Line. Narrated by Anthony Valentine 30 September Fly-by-wire: Technology on Trial 7 October The Light Stuff, about a human-powered aircraft from Santorini to Crete, the MIT Daedalus; the title is from The Right Stuff; the project had taken three years, to fly across the Aegean Sea; the aircraft weighed around 30 kg; to gain the Kremer prize, SUMPAC of the University of Southampton made the first human-powered flight in November 1961, followed by HMPAC Puffin, of de Havilland in Hertfordshire, in May 1962; the Bristol Jupiter flew in 1972; in 1977 Paul MacCready designed his Condor, and his Albatross flew across the English Channel on 12 June 1979, with Bryan Allen; John Langford of MIT developed the Monarch aircraft in 1983, which flew at 21 mph; the Daedalus project began in 1985, to make a 72 mile flight; Steven R.
Sources: en.wikipedia.org
== Further reading == Melik, James (8 July 2009). "Danone's yogurt strategy for Bangladesh". BBC. Kiviat, Barbara (23 August 2010). "Danone's Cheap Trick". Time. Faizul Latif Chowdhury : "The Business of 'Social Business'", The New Age, Dhaka.
The production of Champagne and many sparkling wines requires a second fermentation to occur in the bottle in order to produce the carbonation necessary for the style. A small amount of sugared liquid is added to individual bottles, and the yeast is allowed to convert this to more alcohol and carbon dioxide. The lees are then ricked into the neck of the bottle, frozen, and expelled via pressure of the carbonated wine.
The 9th Marine Infantry Brigade (French: 9e Brigade d'Infanterie de Marine, 9e BIMa) is a light armoured, amphibious unit of the Troupes de marine of the French Army. In July 1963, the 9e Brigade was created in Brittany. On 1 January 1976, the 9th Brigade became the 9th Marine Infantry Division (9e division d'Infanterie de Marine, 9e DIMa), attached to the land intervention force, then the Rapid Action Force from 1984. On 1 July 1999, the 9th Marine Infantry Division became the 9th Marine Light Armoured Brigade. On 1 January 2013, the unit was renamed to the 9th Marine Infantry Brigade (French: 9e Brigade d'Infanterie de Marine, 9e BIMa).
Sources: en.wikipedia.org
Cossack forces played an important role in Russia's wars of the 18th–20th centuries, including the Great Northern War, the Seven Years' War, the Crimean War, the Napoleonic Wars, the Caucasus War, many Russo-Persian Wars, many Russo-Turkish Wars, and the First World War. In the late 19th and early 20th centuries, the Tsarist regime used Cossacks extensively to perform police service. Cossacks also served as border guards on national and internal ethnic borders, as had been the case in the Caucasus War. During the Russian Civil War, Don and Kuban Cossacks were the first people to declare open war against the Bolsheviks. In 1918, Russian Cossacks declared their complete independence, creating two independent states, the Don Republic and the Kuban People's Republic, and the revived Hetmanate emerged in Ukraine. Cossack troops formed the effective core of the anti-Bolshevik White Army, and Cossack republics became centers for the anti-Bolshevik White movement. With the victory of the Red Army, Cossack lands were subjected to decossackization and the Holodomor famine. As a result, during the Second World War, their loyalties were divided and both sides had Cossacks fighting in their ranks. Following the dissolution of the Soviet Union, the Cossacks made a systematic return to Russia. Many took an active part in post-Soviet conflicts. In the 2002 Russian Census, 140,028 people reported their ethnicity as Cossack. There are Cossack organizations in Russia, Kazakhstan, Ukraine, Belarus, and the United States.
== Related enzymes == Other enzymes involved in the catabolism of phenylalanine include phenylalanine hydroxylase, aminotransferase, p-hydroxyphenylpyruvate dioxygenase, homogentisate oxidase, and fumarylacetoacetate hydrolase. Mutations in some of these enzymes can lead to more severe diseases such as, phenylketonuria, alkaptonuria, and tyrosinemia. The gene GSTZ1 is located on chromosome 14q24.3.
== Valuation == The nature of a drug development project is characterised by high attrition rates, large capital expenditures, and long timelines. This makes the valuation of such projects and companies a challenging task. Not all valuation methods can cope with these particularities. The most commonly used valuation methods are risk-adjusted net present value (rNPV), decision trees, real options, or comparables. The most important value drivers are the cost of capital or discount rate that is used, phase attributes such as duration, success rates, and costs, and the forecasted sales, including cost of goods and marketing and sales expenses. Less objective aspects like quality of the management or novelty of the technology should be reflected in the cash flows estimation.
==== Agrochemicals ==== Agrochemical companies are the second largest users of fine chemicals. Most products have a "pharmaceutical heritage". As a consequence of an intensive M&A activity (Mergers and Acquisitions) over the past 10–20 years, the industry now is more consolidated than the pharmaceutical industry. The top 10 companies, led by Syngenta, Switzerland; Bayer Cropsciences, Germany: Monsanto, USA; BASF Crop Protection, Germany, and Dow Agrosciences, USA have a share of almost 95% of the total 2,000,000 tons / $48.5 billion pesticide output in 2010. Since the 1990s, the R&D effort has been focused mainly on gene modified (GM) seeds. At both Monsanto and DuPont's seed subsidiary, Pioneer Hi-Bred, the GM seed businesses already account for more than 50% of total sales. 100 new LMW agrochemicals were launched between 2000–2009. However, only 8 products achieved sales in excess of $100 million per year. Generics play a bigger role in the agro than in the pharma industry. They represent some 70% of the global market. China National Chemical Corp is the world's largest supplier of generic farm chemicals. Mahkteshim Agan, Israel, and Cheminova, Denmark, rank second and third. Apart from these multibillion-dollar companies, there are hundreds of smaller firms with sales of less than $50 million per year, mainly in India and China. The incidence of the cost of the active ingredient is about 33%, much higher than in drugs.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.